Global Anti-Suicide Drug review

Anti-Suicide Drug Comprehensive Study by Type (Anti-Depressants and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), Application (Hospital, Clinic, Home Use), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2028

Anti-Suicide Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Anti-Suicide Drug Market Scope
An intentional suicide is a death that is made by one self. As a result, people with this trait are prone to mental and emotional issues such as depression, personality disorder, impulsiveness, substance abuse, alcoholism, and financial stress. Changing lifestyles and societal pressures also contribute to the high suicide rate among young adults. Anti-suicide medications, such as antipsychotics and antidepressants, are typically prescribed to patients to prevent suicidal thoughts and attempts. These medications treat the underlying conditions that cause a person to have suicidal thoughts. However, an overdose of these drugs can be fatal, hence they must be administered under the supervision of a physician.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Anti-Suicide Drug market throughout the predicted period.

Pfizer (United States), Johnson & Johnson (United States), AstraZeneca plc (United Kingdom), Eli Lilly and Company (United States), Allergan plc (Ireland), GlaxoSmithkline plc (United Kingdom), Merck & Co., Inc. (United States), Lundbeck (Denmark) and NeuroRx, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Anti-Suicide Drug market by Type (Anti-Depressants and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist and Antibiotic Analog), by Application (Hospital, Clinic and Home Use) and Region with country level break-up.

On the basis of geography, the market of Anti-Suicide Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
High Investment In Pharmaceuticals Industries

Market Growth Drivers:
High Prevalence Of Suicides In These Regions, Growing In Number Of Patients and Rise In Awareness Of Psychological Disorders

Challenges:
Strict Regulations For Approval Of Anti-Suicide Drugs and Consumer’s Preference Towards Herbal Medicines

Restraints:
Rise In Cost Of Mental Health Programs and Side Effects Associated With Drugs

Opportunities:
Increasing Healthcare Expenditure In Emerging Economies and Rapidly Expansion Of Pharmaceutical Industry

Market Leaders and their Expansionary Development Strategies
On 11 March 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
In August 2022, Johnson & Johnson's Spravato got approved as a first antidepressant for actively suicidal people by The Food and Drug Administration. It is the quick-acting nasal spray will be available to people with suicidal thoughts and a plan to put them into action. This approval helped company to expand its presence in anti-suicide drug market


Key Target Audience
Anti-Suicide Drug Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Anti-Depressants and Anti-Anxiety Drugs
  • Anti-Psychotic Drugs
  • NMDA Antagonist
  • Antibiotic Analog
By Application
  • Hospital
  • Clinic
  • Home Use
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence Of Suicides In These Regions
      • 3.2.2. Growing In Number Of Patients
      • 3.2.3. Rise In Awareness Of Psychological Disorders
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulations For Approval Of Anti-Suicide Drugs
      • 3.3.2. Consumer’s Preference Towards Herbal Medicines
    • 3.4. Market Trends
      • 3.4.1. High Investment In Pharmaceuticals Industries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Suicide Drug, by Type, Application, Distribution Channel and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-Suicide Drug (Value)
      • 5.2.1. Global Anti-Suicide Drug by: Type (Value)
        • 5.2.1.1. Anti-Depressants and Anti-Anxiety Drugs
        • 5.2.1.2. Anti-Psychotic Drugs
        • 5.2.1.3. NMDA Antagonist
        • 5.2.1.4. Antibiotic Analog
      • 5.2.2. Global Anti-Suicide Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Home Use
      • 5.2.3. Global Anti-Suicide Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Anti-Suicide Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Anti-Suicide Drug (Price)
      • 5.3.1. Global Anti-Suicide Drug by: Type (Price)
  • 6. Anti-Suicide Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithkline plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co., Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lundbeck (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NeuroRx, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Anti-Suicide Drug Sale, by Type, Application, Distribution Channel and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-Suicide Drug (Value)
      • 7.2.1. Global Anti-Suicide Drug by: Type (Value)
        • 7.2.1.1. Anti-Depressants and Anti-Anxiety Drugs
        • 7.2.1.2. Anti-Psychotic Drugs
        • 7.2.1.3. NMDA Antagonist
        • 7.2.1.4. Antibiotic Analog
      • 7.2.2. Global Anti-Suicide Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Home Use
      • 7.2.3. Global Anti-Suicide Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Anti-Suicide Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Anti-Suicide Drug (Price)
      • 7.3.1. Global Anti-Suicide Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Suicide Drug: by Type(USD Million)
  • Table 2. Anti-Suicide Drug Anti-Depressants and Anti-Anxiety Drugs , by Region USD Million (2017-2022)
  • Table 3. Anti-Suicide Drug Anti-Psychotic Drugs , by Region USD Million (2017-2022)
  • Table 4. Anti-Suicide Drug NMDA Antagonist , by Region USD Million (2017-2022)
  • Table 5. Anti-Suicide Drug Antibiotic Analog , by Region USD Million (2017-2022)
  • Table 6. Anti-Suicide Drug: by Application(USD Million)
  • Table 7. Anti-Suicide Drug Hospital , by Region USD Million (2017-2022)
  • Table 8. Anti-Suicide Drug Clinic , by Region USD Million (2017-2022)
  • Table 9. Anti-Suicide Drug Home Use , by Region USD Million (2017-2022)
  • Table 10. Anti-Suicide Drug: by Distribution Channel(USD Million)
  • Table 11. Anti-Suicide Drug Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 12. Anti-Suicide Drug Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 13. Anti-Suicide Drug Online Pharmacies , by Region USD Million (2017-2022)
  • Table 14. South America Anti-Suicide Drug, by Country USD Million (2017-2022)
  • Table 15. South America Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 16. South America Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 17. South America Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 18. Brazil Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 19. Brazil Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 20. Brazil Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 21. Argentina Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 22. Argentina Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 23. Argentina Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 24. Rest of South America Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 25. Rest of South America Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 26. Rest of South America Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 27. Asia Pacific Anti-Suicide Drug, by Country USD Million (2017-2022)
  • Table 28. Asia Pacific Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 29. Asia Pacific Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 31. China Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 32. China Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 33. China Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 34. Japan Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 35. Japan Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 36. Japan Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 37. India Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 38. India Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 39. India Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 40. South Korea Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 41. South Korea Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 42. South Korea Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 43. Taiwan Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 44. Taiwan Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 45. Taiwan Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 46. Australia Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 47. Australia Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 48. Australia Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 52. Europe Anti-Suicide Drug, by Country USD Million (2017-2022)
  • Table 53. Europe Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 54. Europe Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 55. Europe Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 56. Germany Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 57. Germany Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 58. Germany Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 59. France Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 60. France Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 61. France Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 62. Italy Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 63. Italy Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 64. Italy Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 65. United Kingdom Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 66. United Kingdom Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 67. United Kingdom Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 68. Netherlands Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 69. Netherlands Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 70. Netherlands Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 71. Rest of Europe Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 72. Rest of Europe Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 73. Rest of Europe Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 74. MEA Anti-Suicide Drug, by Country USD Million (2017-2022)
  • Table 75. MEA Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 76. MEA Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 77. MEA Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 78. Middle East Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 79. Middle East Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 80. Middle East Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 81. Africa Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 82. Africa Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 83. Africa Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 84. North America Anti-Suicide Drug, by Country USD Million (2017-2022)
  • Table 85. North America Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 86. North America Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 87. North America Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 88. United States Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 89. United States Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 90. United States Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 91. Canada Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 92. Canada Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 93. Canada Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 94. Mexico Anti-Suicide Drug, by Type USD Million (2017-2022)
  • Table 95. Mexico Anti-Suicide Drug, by Application USD Million (2017-2022)
  • Table 96. Mexico Anti-Suicide Drug, by Distribution Channel USD Million (2017-2022)
  • Table 97. Anti-Suicide Drug: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Anti-Suicide Drug: by Type(USD Million)
  • Table 108. Anti-Suicide Drug Anti-Depressants and Anti-Anxiety Drugs , by Region USD Million (2023-2028)
  • Table 109. Anti-Suicide Drug Anti-Psychotic Drugs , by Region USD Million (2023-2028)
  • Table 110. Anti-Suicide Drug NMDA Antagonist , by Region USD Million (2023-2028)
  • Table 111. Anti-Suicide Drug Antibiotic Analog , by Region USD Million (2023-2028)
  • Table 112. Anti-Suicide Drug: by Application(USD Million)
  • Table 113. Anti-Suicide Drug Hospital , by Region USD Million (2023-2028)
  • Table 114. Anti-Suicide Drug Clinic , by Region USD Million (2023-2028)
  • Table 115. Anti-Suicide Drug Home Use , by Region USD Million (2023-2028)
  • Table 116. Anti-Suicide Drug: by Distribution Channel(USD Million)
  • Table 117. Anti-Suicide Drug Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 118. Anti-Suicide Drug Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 119. Anti-Suicide Drug Online Pharmacies , by Region USD Million (2023-2028)
  • Table 120. South America Anti-Suicide Drug, by Country USD Million (2023-2028)
  • Table 121. South America Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 122. South America Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 123. South America Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 124. Brazil Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 125. Brazil Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 126. Brazil Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 127. Argentina Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 128. Argentina Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 129. Argentina Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 130. Rest of South America Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 131. Rest of South America Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 132. Rest of South America Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 133. Asia Pacific Anti-Suicide Drug, by Country USD Million (2023-2028)
  • Table 134. Asia Pacific Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 135. Asia Pacific Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 136. Asia Pacific Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 137. China Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 138. China Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 139. China Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 140. Japan Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 141. Japan Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 142. Japan Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 143. India Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 144. India Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 145. India Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 146. South Korea Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 147. South Korea Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 148. South Korea Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 149. Taiwan Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 150. Taiwan Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 151. Taiwan Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 152. Australia Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 153. Australia Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 154. Australia Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 155. Rest of Asia-Pacific Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 158. Europe Anti-Suicide Drug, by Country USD Million (2023-2028)
  • Table 159. Europe Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 160. Europe Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 161. Europe Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 162. Germany Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 163. Germany Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 164. Germany Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 165. France Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 166. France Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 167. France Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 168. Italy Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 169. Italy Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 170. Italy Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 171. United Kingdom Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 172. United Kingdom Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 173. United Kingdom Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 174. Netherlands Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 175. Netherlands Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 176. Netherlands Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 177. Rest of Europe Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 178. Rest of Europe Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 179. Rest of Europe Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 180. MEA Anti-Suicide Drug, by Country USD Million (2023-2028)
  • Table 181. MEA Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 182. MEA Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 183. MEA Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 184. Middle East Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 185. Middle East Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 186. Middle East Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 187. Africa Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 188. Africa Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 189. Africa Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 190. North America Anti-Suicide Drug, by Country USD Million (2023-2028)
  • Table 191. North America Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 192. North America Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 193. North America Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 194. United States Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 195. United States Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 196. United States Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 197. Canada Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 198. Canada Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 199. Canada Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 200. Mexico Anti-Suicide Drug, by Type USD Million (2023-2028)
  • Table 201. Mexico Anti-Suicide Drug, by Application USD Million (2023-2028)
  • Table 202. Mexico Anti-Suicide Drug, by Distribution Channel USD Million (2023-2028)
  • Table 203. Anti-Suicide Drug: by Type(USD/Units)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Suicide Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-Suicide Drug: by Application USD Million (2017-2022)
  • Figure 6. Global Anti-Suicide Drug: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Anti-Suicide Drug Share (%), by Country
  • Figure 8. Asia Pacific Anti-Suicide Drug Share (%), by Country
  • Figure 9. Europe Anti-Suicide Drug Share (%), by Country
  • Figure 10. MEA Anti-Suicide Drug Share (%), by Country
  • Figure 11. North America Anti-Suicide Drug Share (%), by Country
  • Figure 12. Global Anti-Suicide Drug: by Type USD/Units (2017-2022)
  • Figure 13. Global Anti-Suicide Drug share by Players 2022 (%)
  • Figure 14. Global Anti-Suicide Drug share by Players (Top 3) 2022(%)
  • Figure 15. Global Anti-Suicide Drug share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2022
  • Figure 19. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 21. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 25. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 27. GlaxoSmithkline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithkline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Lundbeck (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Lundbeck (Denmark) Revenue: by Geography 2022
  • Figure 33. NeuroRx, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. NeuroRx, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Global Anti-Suicide Drug: by Type USD Million (2023-2028)
  • Figure 36. Global Anti-Suicide Drug: by Application USD Million (2023-2028)
  • Figure 37. Global Anti-Suicide Drug: by Distribution Channel USD Million (2023-2028)
  • Figure 38. South America Anti-Suicide Drug Share (%), by Country
  • Figure 39. Asia Pacific Anti-Suicide Drug Share (%), by Country
  • Figure 40. Europe Anti-Suicide Drug Share (%), by Country
  • Figure 41. MEA Anti-Suicide Drug Share (%), by Country
  • Figure 42. North America Anti-Suicide Drug Share (%), by Country
  • Figure 43. Global Anti-Suicide Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Johnson & Johnson (United States)
  • AstraZeneca plc (United Kingdom)
  • Eli Lilly and Company (United States)
  • Allergan plc (Ireland)
  • GlaxoSmithkline plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Lundbeck (Denmark)
  • NeuroRx, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 224 Pages 79 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Suicide Drug review Quantitative research analysis
Global Anti-Suicide Drug review Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Anti-Suicide Drug study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Anti-Suicide Drug Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Anti-Suicide Drug market is expected to see growth rate of xx%.
The Anti-Suicide Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Anti-Suicide Drug review Report?

Have a Query? Click Here

Other Related Reports

Actinic Keratosis Drugs Comprehensive Study by Type (Nucleoside metabolic inhibitors, Immunomodulators, Photosensitizing agents, NSAIDs), Way of Intake (Tablets, Cream, Other), End User (Hospitals, C...
$ 3450
Medium-chain Triglycerides Comprehensive Study by Type (Caprylic Acid, Capric Acid, Lauric Acid, Caproic Acid), Application (Nutritional Diet, Personal Care, Pharmaceuticals, Sports Drinks, Infant Fo...
$ 3450
Antacid Tablet Comprehensive Study by Type (Ca-based, Mg-based, Mixed), Application (In-Patient, Out-Patient), Distribution Chanel (Hospital Pharmacies, Retail Pharmacies, Others) Players and Region ...
$ 3500
Neisseria meningitidis Infections Drug Comprehensive Study by Type (Penicillin, Ampicillin, Ceftriaxone), End-users (Hospital, Clinic, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmac...
$ 3350
Cholera Vaccine Comprehensive Study by Type (Shanchol, Dukoral, Vaxchora, Others), End-users (Hospital, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others), Serogroup ...
$ 3350
Anti Acne Drugs Comprehensive Study by Type (Accutane, Benzamycin, Cleocin T, Desquam-E, Erythromycin topical, Minocin, Retin-A), Mode of Administration (Injectable, Oral, Topical), Distribution Chan...
$ 3450